INTRODUCTION
Surfactants, long the primary treatment for infant respiratory distress
syndrome (IRDS), are now being investigated for application to Acute Respiratory
Distress Syndrome (ARDS). To date, however, clinical trials have produced mixed
results.
SCOPE OF THIS REPORT
- Analysis based on review of the most recent published reports of clinical
trials results evaluating potential ARDS therapies
- Summary of treatment practices and unmet clinical need in ARDS
REPORT HIGHLIGHTS
Five surfactants are already marketed for the related condition, IRDS.
Surfactants remain the most promising class of drugs in development for ARDS.
While other drug classes, such as glucocorticoids, have also been investigated
for use in ARDS therapy, trial results have proved disappointing.
KEY REASONS TO BUY THIS REPORT
- To evaluate potential commercial opportunities in a market having no
approved drugs
- To assess competitors in the respiratory market
View Cart
